About Enhancer
| Enhancer ID: | E_00601 |
| Species: | Homo sapiens |
| Position : | chr13:27950000-27980000   |
| Year: | 2022 |
| Title: | Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | B-cell acute lymphoblastic leukemia |
| PMID: | 35316324 |
| MONDO: | MONDO:0004945 |
| Tissue: | Bone Marrow |
| Tissue Ontology ID: | UBERON:0002371 |
| Cell Source: | primary human B-ALL blasts |
| CVCL ID: | |
| Cell Type: | B lymphoblast |
| Cell Ontology ID: | CL:0000945 |
| Experiment Type: | Histone modification ChIP-seq, Chromosome conformation capture sequencing, CRISPR interference |
| High Throughput Method: | H3K27ac ChIP-seq, H3K4me3 ChIP-seq, ATAC-seq, 4C-seq |
| Low Throughput Method: | RT-RT-qPCR, Western blot |
About Target Gene
| Target gene : | FLT3 |
About TF
| TF name : |
About Regulatory State
| Regulatory State : | Active |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|
Enhancer Associated Network
Expression of Target Genes for the Enhancer